Page 212 - Read Online

Galletti et al. Using CTCs in prostate cancer

46. Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, resistance to androgen receptor inhibitors in prostate cancer. Nat Rev
Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Cancer 2015;15:701-11.
Bander NH, Nanus DM, Giannakakou P. Functional characterization 59. Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile
of circulating tumor cells with a prostate-cancer-specific microfluidic A, Stadler WM, Vander Griend DJ, Szmulewitz RZ. Quantitative
device. PLoS One 2012;7:e35976. characterization of androgen receptor protein expression and cellular
47. Sperger JM, Strotman LN, Welsh A, Casavant BP, Chalmers Z, Horn localization in circulating tumor cells from patients with metastatic
S, Heninger E, Thiede S, Tokar J, Gibbs BK, Guckenberger DJ, castration-resistant prostate cancer. J Transl Med 2014;12:313.
Carmichael L, Dehm SM, Stephens PJ, Beebe DJ, Berry SM, Lang 60. Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S,
JM. Integrated analysis of multiple biomarkers from circulating tumor Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S,
cells enabled by exclusion-based analyte isolation. Clin Cancer Res Figueiredo I, Flohr P, Nowakowska K, de Bono JS, Terstappen LW,
2016; doi: 10.1158/1078-0432.CCR-16-1021. Attard G. Androgen receptor expression in circulating tumour cells
48. Gerges N, Rak J, Jabado N. New technologies for the detection of from castration-resistant prostate cancer patients treated with novel
circulating tumour cells. Br Med Bull 2010;94:49-64. endocrine agents. Br J Cancer 2015;112:1166-74.
49. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani 61. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M,
F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu
D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran
Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady S, Haber DA. Androgen receptor signaling in circulating tumor cells
G, Dive C. Tumorigenicity and genetic profiling of circulating tumor as a marker of hormonally responsive prostate cancer. Cancer Discov
cells in small-cell lung cancer. Nat Med 2014;20:897-903. 2012;2:995-1003.
50. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, 62. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D,
Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander
B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber NH, Nanus DM, Giannakakou P. Taxane-induced blockade to nuclear
DA, Toner M. Microfluidic, marker-free isolation of circulating tumor accumulation of the androgen receptor predicts clinical responses in
cells from blood samples. Nat Protoc 2014;9:694-710. metastatic prostate cancer. Cancer Res 2011;71:6019-29.
51. Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, 63. Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K,
Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart
Jansen H, Propping C, Sterzynska K, Dyszkiewicz W, Zabel M, J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella
Kiechle M, Reuning U, Schmitt M, Lucke K. A novel method for the L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ,
in vivo isolation of circulating tumor cells from peripheral blood of Eisenberger MA, Nanus DM, Saad F, Giannakakou P, TAXYNERGY
cancer patients using a functionalized and structured medical wire. Int Investigators. Randomized, noncomparative, Phase II trial of early
J Oncol 2012;41:1241-50. switch from docetaxel to cabazitaxel or vice versa, with integrated
52. Theil G, Fischer K, Weber E, Medek R, Hoda R, Lucke K, Fornara P. biomarker analysis, in men with chemotherapy-naive, metastatic,
The use of a new cellcollector to isolate circulating tumor cells from the castration-resistant prostate cancer. J Clin Oncol 2017; doi: 10.1200/
blood of patients with different stages of prostate cancer and clinical JCO.2017.72.4138.
outcomes - a proof-of-concept study. PLoS One 2016;11:e0158354. 64. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X,
53. Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preisser F, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. A
Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabieres novel androgen receptor splice variant is up-regulated during prostate
C, Riethdorf S, Beyer B, Schlomm T, Pantel K. Improved detection cancer progression and promotes androgen depletion-resistant growth.
of circulating tumor cells in non-metastatic high-risk prostate cancer Cancer Res 2009;69:2305-13.
patients. Sci Rep 2016;6:39736. 65. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel
54. Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate
Clevers H. Organoid culture systems for prostate epithelial and cancer SR. Castration resistance in human prostate cancer is conferred by a
tissue. Nat Protoc 2016;11:347-58. frequently occurring androgen receptor splice variant. J Clin Invest
55. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, 2010;120:2715-30.
Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai 66. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.
M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran Androgen receptor splice variants mediate enzalutamide resistance
L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino in castration-resistant prostate cancer cell lines. Cancer Res
PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, 2013;73:483-9.
Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, 67. Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella
Scher HI, Clevers H, Sawyers CL, Chen Y. Organoid cultures derived RL, Corey E, Nanus DM, Plymate SR, Giannakakou P. Androgen
from patients with advanced prostate cancer. Cell 2014;159:176-87. receptor splice variants determine taxane sensitivity in prostate
56. Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli J, Ware KE, cancer. Cancer Res 2014;74:2270-82.
Gregory S, Armstrong AJ. Whole genomic copy number alterations 68. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M,
in circulating tumor cells from men with abiraterone or enzalutamide Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA,
resistant metastatic castration-resistant prostate cancer. Clin Cancer Luo J. Androgen receptor splice variant 7 and efficacy of taxane
Res 2017;23:1346-57. chemotherapy in patients with metastatic castration-resistant prostate
57. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, cancer. JAMA Oncol 2015;1:582-91.
Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai 69. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson
N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene
Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA. RNA- SB, Heller G, Marrinucci D, Fleisher M, Dittamore R. Association of
Seq of single prostate CTCs implicates noncanonical Wnt signaling in AR-V7 on circulating tumor cells as a treatment-specific biomarker
antiandrogen resistance. Science 2015;349:1351-6. with outcomes and survival in castration-resistant prostate cancer.
58. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of JAMA Oncol 2016;2:1441-9.
204 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 27, 2017